Phaseline

Targets › STAT3

STAT3 (Signal transducer and activator of transcription 3): drug programs, companies and trials

3 programs from 3 companies in 6 trials: 3 Phase 2, 3 Phase 1; Oncology; next expected readout Dec 2027.

Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF, LEP and other growth factors. Once activated, recruits coactivators, such as NCOA1 or MED1, to the promoter region of the target gene. (UniProt, P40763)

Open in Phaseline: the race on STAT3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Northwestern UniversityWP1066
STAT3 inhibitor
STAT3Phase 2Glioblastoma, IDH-WildtypeDec 2027
AstraZenecaDanvatirsen
STAT-3 mRNA 3'UTR antisense inhibitor
STAT3Phase 2Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer (NSCLC); Advanced Colorectal Carcinoma; AML/MDS–
University of Colorado, DenverNT219
IRS1/2 and STAT3 inhibitor
IRS1, IRS2, STAT3Phase 1Head and Neck CancerFeb 2030

Conditions

Non-Small Cell Lung Cancer (1) Metastatic Non-Small Cell Lung Cancer (NSCLC) (1) Advanced Colorectal Carcinoma (1) AML/MDS (1) Glioblastoma, IDH-Wildtype (1) Head and Neck Cancer (1)

Modalities

small molecule (2), mixed (1)

Companies

AstraZeneca (1) Northwestern University (1) University of Colorado, Denver (1)

Related targets

IRS1 (1) IRS2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.